LEGN
Legend Biotech Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-32/100
Last price
18.53
▼ 0.25 (1.33%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
18.76
Prev close
18.78
Day high
19.24
Day low
18.55
Volume
1.35M
Market cap
$3.64B
P/E (TTM)
—
52W range
16.24 – 37.50
Day trading desk
Gap from prior close
-0.08%
Prior close 18.77
VWAP
18.80
-1.44% from price
Relative volume
0.97×
Normal
Session range
13.89%
18.00 – 20.50
Position in range
21%
Near session low
ATR (14D)
0.84
4.52% of price
Prior day high
18.82
PDH
Prior day low
17.92
PDL
Bid / ask spread
—
Quote not published
Session volume
2.30M
Avg 2.37M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.53%
-2.5%
1M
-13.01%
-14.2%
3M
-32.83%
-37.4%
6M
+4.06%
-14.1%
YTD
-13.89%
-28.1%
1Y
-41.61%
-58.0%
3Y
-72.13%
-154.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LEGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+124.20K
Net buying
Buy transactions
9
168.57K shares
Sell transactions
4
44.37K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
3.61M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | SANDERS CORAZON CORSEE D Director |
SELL | 27.37K | $515.10K | Direct |
| Sep 24, 26 | SANDERS CORAZON CORSEE D Director |
STOCK | 20.99K | $0 | Direct |
| Sep 24, 26 | HEYMAN TOMAS J. Director |
STOCK | 20.99K | $0 | Direct |
| Sep 24, 26 | JI DARREN XIAOHUI Director |
STOCK | 28.33K | $0 | Direct |
| Sep 24, 26 | CASEY PATRICK JOHN PH.D. Director |
STOCK | 20.99K | $0 | Direct |
| Sep 24, 26 | MAO LI Director |
STOCK | 20.99K | $0 | Direct |
| Sep 24, 26 | SALOVEY PETER PH.D. Director |
STOCK | 28.33K | $0 | Direct |
| Sep 21, 26 | SANTOS CARLOS E Chief Financial Officer |
STOCK | 19.68K | $0 | Direct |
| Sep 21, 26 | SANTOS CARLOS E Chief Financial Officer |
SELL | 5.43K | $100.62K | Direct |
| Aug 14, 26 | BASH ALAN Chief Executive Officer |
STOCK | 4.91K | $0 | Direct |
| Jun 30, 26 | HUANG YING Chief Executive Officer |
STOCK | 3.38K | $0 | Direct |
| Jun 30, 26 | CASEY PATRICK JOHN PH.D. Director |
SELL | 6.00K | $173.28K | Direct |
| Jun 25, 26 | HUANG YING Chief Executive Officer |
SELL | 5.57K | $158.24K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BASH ALAN |
Chief Executive Officer | 35.14K | Stock Award(Grant) |
CASEY PATRICK JOHN PH.D. |
Director | 69.59K | Stock Award(Grant) |
HEYMAN TOMAS J. |
Director | 53.72K | Stock Award(Grant) |
HUANG YING |
Chief Executive Officer | 238.49K | Stock Gift |
JI DARREN XIAOHUI |
Director | 92.10K | Stock Award(Grant) |
MAO LI |
Director | 65.32K | Stock Award(Grant) |
SALOVEY PETER PH.D. |
Director | 55.10K | Stock Award(Grant) |
SANDERS CORAZON CORSEE D |
Director | 52.73K | Sale |
SANTOS CARLOS E |
Chief Financial Officer | 14.25K | Stock Award(Grant) |
Fundamentals
Market cap$3.64B
Enterprise value$2.94B
Revenue (TTM)$1.27B
Gross profit$719.30M
EBITDA$-41.60M
Net income$-91.50M
EPS (TTM)$-0.52
Free cash flow$27.19M
Total cash$964.60M
Total debt$278.20M
Book value / share$6.35
Shares outstanding194.49M
Float193.54M
Short % of float17.80%
Dividend yield0.00%
Beta (5Y)0.57
Valuation & profitability ratios
Trailing P/E—
Forward P/E17.83
PEG ratio—
Price / sales—
Price / book2.95
EV / revenue2.31
EV / EBITDA-70.70
Gross margin56.57%
Operating margin14.89%
Profit margin-7.20%
Return on equity-8.08%
Return on assets-1.92%
Debt / equity22.63
Current ratio3.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.03B | $627.30M | $285.10M | $117.00M | +64.0% |
| Operating revenue | $1.03B | $621.00M | $285.00M | $116.68M | +65.6% |
| Cost of revenue | $408.10M | $234.60M | $144.20M | $65.36M | +74.0% |
| Gross profit | $620.80M | $392.70M | $140.90M | $51.64M | +58.1% |
| Research & development | $414.70M | $413.50M | $382.20M | $335.65M | +0.3% |
| Selling, general & admin | $341.60M | $284.30M | $201.00M | $174.05M | +20.2% |
| Total operating expense | $757.30M | $702.20M | $669.00M | $507.26M | +7.8% |
| Operating income | -$136.50M | -$309.50M | -$528.10M | -$455.62M | +55.9% |
| Net interest income | $18.70M | $39.60M | $32.70M | -$2.61M | -52.8% |
| Pre-tax income | -$282.60M | -$158.10M | -$520.20M | -$445.72M | -78.7% |
| Tax provision | $14.20M | $18.90M | -$1.90M | $625.00K | -24.9% |
| Net income | -$296.80M | -$177.00M | -$518.30M | -$446.35M | -67.7% |
| Net income to common | -$296.80M | -$177.00M | -$518.30M | -$446.35M | -67.7% |
| Basic EPS | -1.62 | -0.96 | -2.94 | -2.80 | -68.8% |
| Diluted EPS | -1.62 | -0.96 | -2.94 | -2.80 | -68.8% |
| EBIT | -$261.20M | -$136.50M | -$498.40M | -$434.93M | -91.4% |
| EBITDA | -$232.30M | -$115.10M | -$479.90M | -$416.54M | -101.8% |
| Basic shares | 184.32M | 182.85M | 176.08M | 159.04M | +0.8% |
| Diluted shares | 184.32M | 182.85M | 176.08M | 159.04M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $901.90M | $286.70M | $1.28B | $786.03M | — | +214.6% |
| Cash & short-term investments | $948.60M | $1.12B | $1.31B | $1.03B | — | -15.5% |
| Accounts receivable | $13.10M | $6.40M | $100.04M | $90.00K | — | +104.7% |
| Inventory | $32.00M | $23.90M | $19.43M | $10.35M | — | +33.9% |
| Total current assets | $1.25B | $1.28B | $1.50B | $1.10B | — | -2.9% |
| Property, plant & equipment | $402.00M | $201.60M | $189.68M | $161.67M | — | +99.4% |
| Goodwill & intangibles | $74.60M | $174.30M | $155.28M | $68.69M | — | -57.2% |
| Total assets | $1.73B | $1.67B | $1.85B | $1.33B | — | +3.8% |
| Total current liabilities | $636.40M | $277.70M | $216.42M | $297.79M | — | +129.2% |
| Current debt | $319.10M | — | — | — | — | — |
| Long-term debt | — | $301.20M | $281.33M | $260.93M | $120.46M | — |
| Total debt | $413.70M | $350.60M | $328.67M | $284.53M | — | +18.0% |
| Total liabilities | $731.60M | $629.60M | $597.24M | $586.65M | — | +16.2% |
| Retained earnings | -$1.96B | -$1.66B | -$1.48B | -$966.46M | — | -17.9% |
| Shareholder equity | $1.00B | $1.04B | $1.25B | $744.31M | — | -3.7% |
| Working capital | $610.70M | $1.01B | $1.28B | $801.33M | — | -39.3% |
| Net tangible assets | $927.50M | $866.30M | $1.10B | $675.63M | — | +7.1% |
| Shares issued | 369.89M | 367.30M | 363.82M | 330.13M | — | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$282.60M | -$158.10M | -$520.20M | -$445.72M | -78.7% |
| Depreciation & amortisation | $28.90M | $21.40M | $18.50M | $18.39M | +35.0% |
| Stock-based compensation | $64.60M | $68.90M | $47.70M | $34.34M | -6.2% |
| Change in working capital | -$93.10M | $18.40M | -$72.70M | $181.03M | -606.0% |
| Operating cash flow | -$100.20M | -$144.00M | -$393.30M | -$201.28M | +30.4% |
| Capital expenditure | -$28.60M | -$14.10M | -$22.70M | -$22.27M | -102.8% |
| Investing cash flow | $709.60M | -$850.60M | $92.90M | -$77.09M | +183.4% |
| Financing cash flow | -$300.00K | $5.70M | $791.40M | $377.98M | -105.3% |
| Free cash flow | -$128.80M | -$158.10M | -$416.00M | -$223.56M | +18.5% |
| End cash position | $901.90M | $286.70M | $1.28B | $786.03M | +214.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $387.50M | $305.10M | $306.38M | $272.33M | $255.10M | +27.0% |
| Operating revenue | $387.50M | $305.10M | $306.19M | $272.31M | $255.10M | +27.0% |
| Cost of revenue | $137.40M | $175.90M | $123.46M | $115.31M | $98.00M | -21.9% |
| Gross profit | $250.10M | $129.20M | $182.92M | $157.02M | $157.10M | +93.6% |
| Research & development | $96.00M | $85.70M | $101.33M | $113.15M | $98.30M | +12.0% |
| Selling, general & admin | $96.40M | $90.10M | $101.19M | $87.33M | $80.70M | +7.0% |
| Total operating expense | $192.40M | $179.00M | $203.52M | $200.48M | $179.00M | +7.5% |
| Operating income | $57.70M | -$49.80M | -$20.60M | -$43.45M | -$21.90M | +215.9% |
| Net interest income | -$200.00K | $1.80M | $2.47M | $4.03M | $5.20M | -111.1% |
| Pre-tax income | $55.50M | -$53.10M | -$19.60M | -$39.07M | -$124.80M | +204.5% |
| Tax provision | $22.30M | $1.20M | $11.22M | $616.00K | $600.00K | +1,758.3% |
| Net income | $33.20M | -$54.30M | -$30.82M | -$39.69M | -$125.40M | +161.1% |
| Net income to common | $33.20M | -$54.30M | -$30.82M | -$39.69M | -$125.40M | +161.1% |
| Basic EPS | 0.18 | -0.30 | -0.16 | -0.22 | -0.68 | +160.0% |
| Diluted EPS | 0.18 | -0.30 | -0.16 | -0.22 | -0.68 | +160.0% |
| EBIT | $61.30M | -$47.60M | -$14.12M | -$33.44M | -$119.60M | +228.8% |
| EBITDA | $73.00M | -$32.00M | -$2.15M | -$27.41M | -$113.80M | +328.1% |
| Basic shares | 187.00M | 185.10M | 184.73M | 184.64M | 184.15M | +1.0% |
| Diluted shares | 193.80M | 185.10M | 184.73M | 184.64M | 184.15M | +4.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $672.90M | $646.40M | $901.90M | $278.89M | $266.59M | — | +4.1% |
| Cash & short-term investments | $964.60M | $834.60M | $948.60M | $992.59M | $967.55M | — | +15.6% |
| Accounts receivable | $0 | $1.70M | $13.10M | $1.24M | $27.58M | — | -100.0% |
| Inventory | $41.50M | $37.10M | $32.00M | $29.18M | $35.59M | — | +11.9% |
| Total current assets | $1.23B | $1.08B | $1.25B | $1.24B | $1.25B | — | +13.4% |
| Property, plant & equipment | $448.20M | $452.50M | $402.00M | $253.74M | $233.60M | — | -1.0% |
| Goodwill & intangibles | $49.80M | $35.00M | $74.60M | $206.21M | $200.78M | — | +42.3% |
| Total assets | $1.75B | $1.60B | $1.73B | $1.71B | $1.69B | — | +9.7% |
| Total current liabilities | $403.60M | $509.10M | $636.40M | $433.57M | $265.48M | — | -20.7% |
| Current debt | $156.40M | $266.00M | $319.10M | $142.87M | — | — | -41.2% |
| Long-term debt | — | — | — | $171.93M | $310.26M | $305.75M | — |
| Total debt | $278.20M | $389.30M | $413.70M | $410.24M | $387.91M | — | -28.5% |
| Total liabilities | $521.30M | $629.00M | $731.60M | $701.69M | $654.38M | — | -17.1% |
| Retained earnings | -$1.98B | -$2.01B | -$1.96B | -$1.93B | -$1.89B | — | +1.6% |
| Shareholder equity | $1.23B | $967.70M | $1.00B | $1.01B | $1.04B | — | +27.1% |
| Working capital | $823.80M | $573.60M | $610.70M | $808.43M | $984.39M | — | +43.6% |
| Net tangible assets | $1.18B | $932.70M | $927.50M | $805.05M | $834.76M | — | +26.5% |
| Shares issued | 387.54M | 371.48M | 369.89M | 369.38M | 369.14M | — | +4.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $55.50M | -$53.10M | -$19.60M | -$39.00M | -$124.80M | +204.5% |
| Depreciation & amortisation | $11.70M | $15.60M | $11.97M | $6.03M | $5.80M | -25.0% |
| Stock-based compensation | $17.40M | $19.30M | $14.94M | $15.06M | $18.70M | -9.8% |
| Change in working capital | -$100.40M | -$75.30M | -$59.97M | $77.17M | -$36.30M | -33.3% |
| Operating cash flow | -$20.90M | -$85.10M | -$12.21M | $28.80M | -$13.20M | +75.4% |
| Capital expenditure | -$7.50M | -$7.50M | -$12.37M | -$5.03M | -$9.20M | 0.0% |
| Investing cash flow | -$120.00M | -$168.00M | $638.49M | -$19.99M | -$165.50M | +28.6% |
| Financing cash flow | $167.70M | -$1.20M | -$647.00K | $647.00K | -$900.00K | +14,075.0% |
| Free cash flow | -$28.40M | -$92.60M | -$24.57M | $23.77M | -$22.40M | +69.3% |
| End cash position | $672.90M | $646.40M | $901.90M | $278.89M | $266.50M | +4.1% |
Options analytics
Put / call volume
0.94
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
10.00
-46.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
322
Contracts, this expiry
Put volume
302
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
12.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.28 | 0.32 | +14.3% |
| Mar 2026 | -0.17 | — | — |
| Dec 2025 | 0.19 | -0.16 | -184.4% |
| Sep 2025 | -0.19 | -0.22 | -18.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.01 | 1 | $358.81M | +31.8% |
| Next quarter | 0.09 | 1 | $381.20M | +24.5% |
| Current year | -0.01 | 1 | $1.43B | +39.0% |
| Next year | 0.68 | 2 | $1.79B | +25.3% |
Analyst targets & ownership
Mean target$46.50
High target$74.00
Low target$24.00
Implied upside151.00%
Analyst count13
ConsensusBUY
Strong buy / Buy5 / 3
Hold5
Sell / Strong sell0 / 0
Held by insiders1.86%
Held by institutions56.85%
Institutions holding342
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.93
-2.16% from price
SMA 20
18.63
+0.47% from price
SMA 50
19.76
-5.29% from price
SMA 100
24.20
-23.45% from price
SMA 200
22.38
-16.35% from price
EMA 12
18.89
-1.91% from price
EMA 26
19.29
-3.94% from price
EMA 50
20.39
-9.13% from price
RSI (14)
45.2
Neutral
MACD (12,26,9)
-0.40
Hist 0.14
ATR (14)
0.84
4.47% of price
Realised vol 30D
46.7%
Annualised
Bollinger upper
20.07
20, 2σ
Bollinger lower
17.20
20, 2σ
50 / 200 cross
Death
19.76 vs 22.38
Trend bias
Below 200
-16.35%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.54
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
46.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-53.1%
Peak to trough
Max drawdown 5Y
-78.2%
Peak to trough
ATR 14
0.84
4.47% of price
Beta (reported)
0.57
5Y monthly, from filing
Short interest
Shares short
14.64M
Prior 17.82M
Change vs prior
-17.9%
Shorts covering
% of float
17.80%
Elevated
% of shares out
7.53%
Against total outstanding
Days to cover
7.4
Crowded exit
Float
193.54M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 11, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| Aug 12, 26 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Aug 12, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 12, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 27, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 24, 26 | UBS | DOWNGRADE | Buy | Neutral |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-25
Corporate Changes & Voting Matters
6-K · 2026-09-24
Corporate Changes & Voting Matters
6-K · 2026-09-15
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-08-18
Corporate Changes & Voting Matters
6-K · 2026-08-11
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-27
Headlines
Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data
Simply Wall St. · 3d ago
Sector Update: Healthcare Stocks Steady Late Afternoon
MT Newswires · 4d ago
Sector Update: Healthcare
MT Newswires · 4d ago
Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
MT Newswires · 5d ago
Legend Biotech Insider Sold Shares Worth $258,920, According to a Recent SEC Filing
MT Newswires · 5d ago
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
GlobeNewswire · 6d ago
Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT Newswires · 8d ago
Legend Biotech Says Five-Year Carvykti Data Show 50% of Patients Remained Progression-Free and Alive
MT Newswires · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.